MOE Key Laboratory of Macromolecule Synthesis and Functionalization of Ministry of Education, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, 310058, PR China.
Department of Surgery, The Fourth Affiliated Hospital, International Institutes of Medicine, Zhejiang University School of Medicine, Yiwu, 322000, PR China.
Biomaterials. 2025 Jan;312:122743. doi: 10.1016/j.biomaterials.2024.122743. Epub 2024 Aug 6.
Photodynamic therapy (PDT) is an appealing modality for cancer treatments. However, the limited tissue penetration depth of external-excitation light makes PDT impossible in treating deep-seated tumors. Meanwhile, tumor hypoxia and intracellular reductive microenvironment restrain the generation of reactive oxygen species (ROS). To overcome these limitations, a tumor-targeted self-illuminating supramolecular nanoparticle T-NP is proposed by integrating photosensitizer Ce6 with luminol and nitric oxide (NO) for chemiluminescence resonance energy transfer (CRET)-activated PDT. The high HO level in tumor can trigger chemiluminescence of luminol to realize CRET-activated PDT without exposure of external light. Meanwhile, the released NO significantly relieves tumor hypoxia via vascular normalization and reduces intracellular reductive GSH level, further enhancing ROS abundance. Importantly, due to the different ROS levels between cancer cells and normal cells, T-NP can selectively trigger PDT in cancer cells while sparing normal cells, which ensured low side effect. The combination of CRET-based photosensitizer-activation and tumor microenvironment modulation overcomes the innate challenges of conventional PDT, demonstrating efficient inhibition of orthotopic and metastatic tumors on mice. It also provoked potent immunogenic cell death to ensure long-term suppression effects. The proof-of-concept research proved as a new strategy to solve the dilemma of PDT in treatment of deep-seated tumors.
光动力疗法(PDT)是一种有吸引力的癌症治疗方法。然而,外部激发光的有限组织穿透深度使得 PDT 无法用于治疗深部肿瘤。同时,肿瘤缺氧和细胞内还原微环境抑制了活性氧(ROS)的产生。为了克服这些限制,通过将光敏剂 Ce6 与鲁米诺和一氧化氮(NO)集成,提出了一种肿瘤靶向自照明超分子纳米颗粒 T-NP,用于化学发光共振能量转移(CRET)激活 PDT。肿瘤中高的 HO 水平可以触发鲁米诺的化学发光,从而在不暴露外部光的情况下实现 CRET 激活 PDT。同时,释放的 NO 通过血管正常化显著减轻肿瘤缺氧,并降低细胞内还原 GSH 水平,进一步增加 ROS 丰度。重要的是,由于癌细胞和正常细胞之间的 ROS 水平不同,T-NP 可以选择性地在癌细胞中触发 PDT,而不会损伤正常细胞,从而确保低副作用。基于 CRET 的光敏剂激活和肿瘤微环境调节的组合克服了传统 PDT 的固有挑战,在小鼠中有效地抑制了原位和转移性肿瘤。它还引发了有效的免疫原性细胞死亡,以确保长期的抑制效果。这一概念验证研究为解决深部肿瘤 PDT 治疗的困境提供了一种新策略。